Lisata Therapeutics (NASDAQ:LSTA) Issues Earnings Results, Beats Expectations By $0.41 EPS

Lisata Therapeutics (NASDAQ:LSTA) posted its earnings results on Thursday. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.74) by $0.41, FiscalAI reports. The company had revenue of $0.10 million during the quarter.

Lisata Therapeutics Stock Performance

LSTA stock traded down $0.01 on Friday, hitting $5.02. 17,570 shares of the company’s stock were exchanged, compared to its average volume of 203,106. The firm has a 50 day moving average price of $3.87 and a two-hundred day moving average price of $2.81. Lisata Therapeutics has a 12-month low of $1.81 and a 12-month high of $5.07. The stock has a market cap of $44.29 million, a P/E ratio of -2.37 and a beta of 1.28.

Analysts Set New Price Targets

Several analysts have commented on the stock. Brookline Capital Acquisition lowered shares of Lisata Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lisata Therapeutics in a research report on Thursday, January 22nd. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $23.50.

Institutional Investors Weigh In On Lisata Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Cerity Partners LLC purchased a new stake in shares of Lisata Therapeutics during the second quarter worth about $32,000. CIBC Bancorp USA Inc. purchased a new position in shares of Lisata Therapeutics in the 3rd quarter valued at approximately $37,000. Finally, Renaissance Technologies LLC boosted its stake in Lisata Therapeutics by 6.1% in the 4th quarter. Renaissance Technologies LLC now owns 123,715 shares of the company’s stock worth $230,000 after purchasing an additional 7,093 shares in the last quarter. Institutional investors and hedge funds own 8.94% of the company’s stock.

About Lisata Therapeutics

Lisata Therapeutics, Inc (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches.

Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies.